In the last two years, federated networks, decentralized trials, and other digital innovations have quickly shifted from "emerging trend" to "must have" for both clinical and commercial success. Taking advantage of these trends requires a new and different focus on Enterprise Information Management (EIM) far beyond the "we'll migrate to the cloud" strategy that organizations have relied on over the past five years. This paper provides an overview on how EIM supports this transition and what core capabilities need to be re-assessed so company strategies evolve at the pace of their digital transformation.
"The new EIM mission in life sciences requires extensible capabilities that span molecule-to-market business functions and can be applied across information pathways, data sources, and analytics as a horizontal capability" says Luke Dunlap, Senior Principal, Global Head, Information Management Strategy."